Octreotide use and safety in infants with hyperinsulinism
نویسندگان
چکیده
منابع مشابه
Safety of octreotide in hospitalized infants.
BACKGROUND Octreotide is used off-label in infants for treatment of chylothorax, congenital hyperinsulinism, and gastrointestinal bleeding. The safety profile of octreotide in hospitalized infants has not been described; we sought to fill this information gap. METHODS We identified all infants exposed to at least 1 dose of octreotide from a cohort of 887,855 infants discharged from 333 neonat...
متن کاملSuccessful treatment of congenital hyperinsulinism with long-acting release octreotide.
CONTEXT Congenital hyperinsulinism (HI) is a common cause of hypoglycemia in infancy. The medical treatment of diazoxide-unresponsive HI is based on a somatostatin analogue. OBJECTIVE This study aims at replacing three daily s.c. octreotide (Sandostatin, Novartis) injections by a single and monthly i.m. injection of long-acting release (LAR) octreotide (Sandostatin LP, Novartis) in HI patient...
متن کاملLate Presentation of Fulminant Necrotizing Enterocolitis in a Child with Hyperinsulinism on Octreotide Therapy.
Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in infants and children. In cases of diazoxide-unresponsive HI, alternative medical and surgical approaches may be required to reduce the risk of hypoglycemia. Octreotide, a somatostatin analog, often has a role in the management of these children, but a dose-dependent reduction in splanchnic blood flow is a rec...
متن کاملLate Presentation of Fulminant Necrotizing Enterocolitis in a Child with Hyperinsulinism on Octreotide Therapy
Congenital hyperinsulinism (HI) is the most common cause of persistent hypoglycemia in infants and children. In cases of diazoxide-unresponsive HI, alternative medical and surgical approaches may be required to reduce the risk of hypoglycemia. Octreotide, a somatostatin analog, often has a role Received: December 18, 2015 Accepted: January 12, 2016 Published online: February 12, 2016 HORMONE
متن کاملA New Experience in Treatment of Congenital Hyperinsulinism with Long Acting Octreotide: A Case Report
Histologically, congenital hyperinsulinism may be broadly classified into focal and diffuse forms. Although they present with similar clinical manifestations, they differ in the management required. Focal forms of CHI, unlike the diffuse forms are amenable to surgery without any long term sequlae [4]. Owing to the fact that, near-total pancreactectomy often leads to postoperative hypoglycemias ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacoepidemiology and Drug Safety
سال: 2016
ISSN: 1053-8569
DOI: 10.1002/pds.4144